EU fidaxomicin approval another feather in Optimer's 2011 cap
This article was originally published in Scrip
In the second major regulatory clearance for the product this year, the European Commission has granted a marketing authorisation to Optimer Pharmaceuticals/Astellas' first-in-class antibiotic for Clostridium difficile infections Dificlir (fidaxomicin), clearing the way for a new treatment option for what can be a fatal disorder.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.